Another two VDAC1-specific small molecules, VBIT-4 and VBIT-12, were recently tested as therapeutic targets for ALS, both in vitro and in vivo (Table 1) [56]. This evidence concerns the gene VDAC1 and amyotrophic lateral sclerosis.